平消胶囊对手术后Ⅰ~Ⅱa期非小细胞肺癌的治疗分析
平消胶囊;,Ⅰ~Ⅱa期非小细胞肺癌,,平消胶囊;,Ⅰ~Ⅱa期非小细胞肺癌,1资料和方法,2结果,3讨论,参考文献
【摘要】 目的: 观察平消胶囊对手术后Ⅰ~Ⅱa期非小细胞肺癌的1、3年生存率,免疫功能及生存质量的影响。方法: 全部患者均经病理证实的非小细胞肺癌。根据临床和术后病理确定为Ⅰ~Ⅱa期,Karnofsky评分≥70分,年龄在35~75岁。治疗组术后两周给予平消胶囊治疗,一次4~5粒,3次/d,90d为一疗程,对照组术后不给予任何治疗。治疗结束后对两组病人的1、3年生存率,免疫功能及生存质量进行评估。结果: 治疗组1、3年生存率分别为955%、665%;对照组为940%、645%。两组1、3年生存率差异无显著性(P>005),治疗组外周血T细胞亚群、T淋巴细胞的比值明显高于对照组(P<005)。生存质量(生活质量调查、体重、卡氏评分)明显高于对照组(P<005)。结论: 平消胶囊具有增加患者免疫力及提高生存质量的作用,但对术后Ⅰ~Ⅱa期非小细胞肺癌的生存率(1、3年生存率)无明显影响。【关键词】 平消胶囊; Ⅰ~Ⅱa期非小细胞肺癌
Analysis on the Treatment with Pingxiao Capsule for Ⅰ~Ⅱa NSCLC
ZHANG Zhenming, ZHU Decheng, DONG Yuehua
The First Affiliated Hospital,Hebei North University,Zhangjiakou,075000,Hebei, China
【ABSTRACT】 Objective: To investigate the survival rate in one and three years,the immunity and living quality while the Ⅰ~Ⅱa NSCLC patients were treated with Pingxiao Capsule after operation.Methods:The patients confirmed suffering from non small cell lung cancer(NSCLC) were diagnosed being in the Ⅰ~Ⅱa period,Karnofsky≥70,35~70 years old (including 35 and 75).The group was treated with Pingxiao Capsule,4~5 capsules pertime,three times a day,taking 90 days as treating course,but the control group didnt receive any treatment.After the treatment ended,the survival rate, immunity and living quality were evaluated.Results:For the treated group,the survival rates for one and three years were 955% and 665% separately.For the control group,the rates of that were 940% and 645%.There is no significant differece between the two groups(P>005).The specific data of outside Tcell submass and limphcell in the treated group was higher than that of the control group(P<005).The treated groups living quality(living quality form of questionnaire,weight,calculative mark) was higher than that of the control group(P<005).Conclusion:Pingxiao Capsule has the function to improve patients immunity and living quality.But there is no remarkable affect on survival rate of the patients suffering from nonsmall cell lung cancer after operation. ......
您现在查看是摘要页,全文长 6684 字符。